Here you can access to information about organisations operating in the Health sector in the cross-border cooperation region of Galicia (Spain) - Norte (Portugal), and find/announce opportunities to establish new scientific, technological, clinical or commercial partnerships with these organisations. You’re free to access all the information available so far. If you want to announce an opportunity, and you're not registered yet, please register here.

[HIPOD's starting date: 18 January 2019]

Opportunities: Offer
Opportunities: Demand
News & Events
Galicia (Spain) | Biotech Company; Contract Manufacturing Organisation; Other
Experienced Director of Global Strategic Program and Portfolio Management with a demonstrated background in biotechnology industry with several products taken from early development to commercialization. Passionate and skilled in strategy, team management, with strong interpersonal skills fostering customer happiness. MBA graduate with major in entrepreneurship. Private Investor and Board Member at Qubiotech Health Intelligence and ChemoSapiens
Galicia (Spain) | Biotech Company
Nanoimmunotech is a nanobiotechnology Spanish SME with a wide knowledge in bioconjugation and biosensors. It was created in 2009 as a spin-off of two research centers with experience in different areas of nanobiotechnology. With venues in Zaragoza and Vigo, the company has great international presence, sells its products and services all over the world and cooperate in global R&D projects. With the purpose of becoming a world referent in nanobionsensors, they have launched to the market, HEATSENS®, a new disruptive technology of which the company has the exclusive patent and license.
Galicia (Spain) | Consultancy & Business Development Company
UN-EM is a company created to advise Universities and Technological Centers to transfer research results to the market. The staff is specialized in technologies valuation, boosting entrepreneurship and the creation of Spin-Off companies. UN-EM facilitate the commercial exploitation of scientific results. The company is based on knowledge and methodologies which allows break down geographical barriers, with customers in Spain and Latin America.
Norte (Portugal) | Public / Nonprofit Organisation
The INL International Iberian Nanotechnology Laboratory, located in Braga (North of Portugal) was founded by the governments of Portugal and Spain under an international legal framework to perform interdisciplinary research, deploy and articulate nanotechnology for the benefit of society. INL aims to become the world-wide hub for nanotechnology addressing society’s grand challenges.
Galicia (Spain) | Academic Institution; R&D Institution; Science & Technology Parks, Incubators, or Technology Transfer Organisations
With more than 1,000 researchers dedicated to biotechnology and biomedicine, a Campus of International Excellence, CAMPUS VIDA, and 30 years of experience in valorization and transfer of research results, the USC has a portfolio of more than 200 patents and 40 spin-off based on the knowledge generated by its researchers.
Norte (Portugal) | Medtech Company
BestHealth4U is developing and bringing to market a new generation of medical-grade adhesives. Bio2Skin is our revolutionary nano-based adhesive for medical applications and can be integrated into a wide range of medical devices. It is based on a patented-pending technology, that avoids skin injury in prolonged use or upon removal. It is ideal for general use and can provide effective protection against Medical Adhesive-Related Skin Injury (MARSI) in long-term applications such as ostomy, elderly and neo-natal patients. The treatment of the skin damage is costly in terms of service provision, time, and in severe cases requires long periods of hospitalizations due to infection. Besides mechanical injury, medical adhesives can induce dermatitis (either irritant or allergic) and other types of skin damage such as maceration of folliculitis. Age-related physiologic factors exert a significant impact on a patient’s susceptibility with the elderly and neonates the most vulnerable. In 2012, it was calculated that about €900 million in payments to hospitals in USA were withheld because of MARSI. Currently available adhesives are artificially produced viscous materials that fill the skin irregularities, to augment the contact area. When they are removed, they tend to provoke dermatitis, which is due to the removal of a large amount of epidermis cells. Bio2Skin is inspired by forces in nature which results from the combination of highly biocompatible chemically-modified polymers. The adhesive developed by BestHealth4U uses polyol polymer produced based on bio-materials and modified polymers. Applications of these materials are based on their intrinsic biocompatibility, biodegradability, and non-toxicity. Bio2Skin displays excellent adhesion properties to match currently used medical-grade adhesives. Bio2Skin binds to the natural features of the skin offering good adhesion properties without damaging the skin either during use or upon removal, reducing or even eliminating the skin damage caused by the continuous use of current adhesives. It can be used in ostomy, wound dressing, hot and cold therapy, wearable medical devices and kinesiology bands. Small-scale pre-clinical tests so far have been extremely promising, and we believe we can make a significant impact in the medical adhesive market which s is projected to reach €10 billion by 2019.
Opportunity Offer
Mentoring | Advanced Therapy Medicinal Products; Pharmaceutical Products; Medical Technologies & In Vitro Diagnostics
The HealthTechTAB is a high-level EC-powered service that operates within the framework of NOBEL, a joint effort to accelerate HealthTech development and provide the HealthTech community, both from industry and academia, with the right tools to bring their innovations to patients.The TAB brings together a pool of industry experts with a solid track record of delivering health tech products from bench to the patients with the sole purpose of accelerating the translation of promising European health tech projects through high-level coaching. The TAB welcomes projects at any stage of development and offers them technical and commercial evaluation together with peer support and guidance. This service is accessible to all European innovators, from academia and industry, for free.For more information about the program, please visit or contact us.
Galicia (Spain) | Public / Nonprofit Organisation
ACIS is the autonomous public agency attached to the Ministry of Health that responds to the need to manage training in the public health system of Galicia, to promote research in health institutions, to promote and coordinate innovation in the health sector and to evaluate health technologies, processes and services. ACIS is the nucleating element of the ecosystem of knowledge and innovation in health in Galicia.
Norte (Portugal) | Pharmaceutical Company; R&D Institution
BIAL is an innovative pharmaceutical company with products available in more than 55 countries. Founded in 1924, BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. The company is committed to improve human health and quality of life for people from all over the world. Its strategic areas are Innovation, Internationalisation and Quality. The company headquarters are located in Portugal. BIAL has also affiliates in Spain, Germany, United Kingdom, Italy, Switzerland, Mozambique, Angola, Ivory Coast and Panama. Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. Key focus areas for the Group are the neurosciences and cardiovascular. BIAL has launched eslicarbazepine acetate, an epilepsy drug, already available in the US and in several European countries. BIAL has also developed a Parkinson’s disease compound, opicapone, also commercialized in Europe. The company expects to introduce more new medicines to the market over the next few years, strengthening its international presence based in its own innovative medicines and accomplishing the purpose of delivering innovative products to patients worldwide. BIAL Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA).